Synthetic Lethality Is Owned, Not for Sale
83 synthetic-lethality oncology assets by target and ownership; the field is largely founder-owned and the public takeout shortlist is just four names.
Download the Visual
A sell-side desk just initiated coverage on synthetic lethality as a category, not a company. When banks cover a mechanism, the thesis has arrived.
So I mapped the field everyone now calls the next ADC-style M&A wave.
There are 83 synthetic-lethality oncology assets across the core targets. 60 are wholly owned, 18 are licensed, and only 5 have ever been acquired. Since 2020 there have been 19 deals: 12 licenses and 7 acquisitions. One buyout, Bristol Myers Squibb's $5.8B Mirati deal, plus the top five transactions, make up 85% of all disclosed value.
The wave is real. It is also mostly licensing on an early, founder-owned field. The two most advanced Phase 3 programs, an ATR lead and a WEE1 lead, are wholly held by AstraZeneca and Zentalis, so neither is for sale. The public pure-plays you could actually buy number four: Aprea and Zentalis on WEE1, PharmaEngine and Tango on PRMT5.
If you are scouting synthetic lethality, the move is not waiting for a bidding war. It is optioning the mid-pipeline now, in crowded leaders like PRMT5, ATR and WRN and in the emerging tail before it prices in.
The teams treating synthetic lethality as a watchlist of options will own the winners. The ones waiting for the wave will pay up for what is left.
